NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rifaximin (Zaxine): For the Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence in Patients ≥ 18 Years of Age [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

Cover of Rifaximin (Zaxine)

Rifaximin (Zaxine): For the Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence in Patients ≥ 18 Years of Age [Internet].

Show details

APPENDIX 1COST COMPARISON

The comparators presented in Table 3 have been deemed to be appropriate by clinical experts. Comparators may be recommended (appropriate) practice versus actual practice. Comparators are not restricted to drugs, but may be devices or procedures. Costs are manufacturers’ list prices, unless otherwise specified.

Table 3. Cost Comparison Table for Zaxine.

Table 3

Cost Comparison Table for Zaxine.

Copyright © CADTH 2015.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK362574

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...